Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06363461 · ClinicalTrials.gov registry record · Phase 2
Study of TDM-180935 in Atopic Dermatitis Patients
A Phase 2 study, sponsored by Technoderma Medicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT06363461: Completed Phase 2 study, sponsored by Technoderma Medicines.
NCT06363461 is a Phase 2 study that has completed, run by Technoderma Medicines. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06363461, a Phase 2 study, has completed, sponsored by Technoderma Medicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients
Primary Outcome
Collection of EASI (Eczema Area and Severity Index) results at week 8. The total m-EASI score may range from zero (0) to a maximum of 64.8, and higher scores mean a worse outcome.
Interventions
- DRUG TDM-180935 topical ointment 1.0%
- DRUG TDM-180935 topical ointment 2.0%
- DRUG TDM-180935 topical vehicle ointment 1
- DRUG TDM-180935 topical vehicle ointment 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-04-13 |
| Est. Completion | 2025-04-08 |
| Phase | Phase 2 |
What the finished NCT06363461 record still lists
NCT06363461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which TDM-180935 topical ointment 1.0% is the first listed.
NCT06363461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06363461 about?
NCT06363461 is a clinical study titled "Study of TDM-180935 in Atopic Dermatitis Patients". Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients
What is the current status of trial NCT06363461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-04-13. Estimated completion is 2025-04-08.
What interventions are being tested in trial NCT06363461?
The interventions under investigation include: TDM-180935 topical ointment 1.0% (DRUG), TDM-180935 topical ointment 2.0% (DRUG), TDM-180935 topical vehicle ointment 1 (DRUG), TDM-180935 topical vehicle ointment 2 (DRUG).
Who is sponsoring clinical trial NCT06363461?
This trial is sponsored by Technoderma Medicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06363461's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI